Hepatology research group Publications

Publications 2024

1. Druckrey-Fiskaaen KT, Vold JH, Madebo T, Midgard H, Dalgard O, Leiva RA, Fadnes LT, INTRO-HCV Study Group (2024)
   Liver stiffness and associated risk factors among people with a history of injecting drugs: a prospective cohort study
   Subst Abuse Treat Prev Policy, 19 (1), 21
   DOI 10.1186/s13011-024-00603-z, PubMed 38532435
2. Johannessen A, Midgard H (2024)
   [Not Available]
   Tidsskr Nor Laegeforen, 144 (9)
   DOI 10.4045/tidsskr.24.0365, PubMed 39166991
3. Malme KB, Stene-Johansen K, Klundby I, Backe Ø, Foshaug T, Greve MH, Pihl CM, Finbråten AK, Dalgard O, Midgard H (2024)
   Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial
   Viruses, 16 (6)
   DOI 10.3390/v16060858, PubMed 38932151
4. Midgard H, Malme KB, Finbråten AK, Dalgard O (2024)
   Treatment completion and SVR in the context of HCV elimination: Time to let go of the reins?
   Clin Infect Dis (in press)
   DOI 10.1093/cid/ciae298, PubMed 38824443
5. Midgard H, Malme KB, Pihl CM, Berg-Pedersen RM, Tanum L, Klundby I, Haug A, Tveter I, Bjørnestad R, Olsen IC, Finbråten AK, Dalgard O (2024)
   Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial
   Clin Infect Dis, 78 (3), 582-590
   DOI 10.1093/cid/ciad711, PubMed 37992203
6. Whittaker R, Midgard H, Dalgard O, Kløvstad H (2024)
   Treatment uptake among notified cases of hepatitis C virus infection in Norway, 1990 to 2022: a registry-based study to monitor progress towards elimination
   Euro Surveill, 29 (46)
   DOI 10.2807/1560-7917.ES.2024.29.46.2400180, PubMed 39544147

Publications 2023

1. Haukeland JW, Vesterhus MN, Jørgensen KK, Frigstad SO, Karlsen TH (2023)
   [The FIB-4 test as a decision-making tool]
   Tidsskr Nor Laegeforen, 143 (5)
   DOI 10.4045/tidsskr.23.0176, PubMed 36987901
2. Malme KB, Ulstein K, Finbråten AK, Wüsthoff LEC, Kielland KB, Hauge J, Dalgard O, Midgard H (2023)
   Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study
   Int J Drug Policy, 116, 104044
   DOI 10.1016/j.drugpo.2023.104044, PubMed 37149914
3. Opheim E, Dalgard O, Ulstein K, Sørli H, Backe Ø, Foshaug T, Couëssurel Wüsthoff LE, Midgard H (2023)
   Towards elimination of hepatitis C in Oslo: Cross-sectional prevalence studies among people who inject drugs
   Int J Drug Policy, 123, 104279
   DOI 10.1016/j.drugpo.2023.104279, PubMed 38061225
4. Polaris Observatory Collaborators (2023)
   Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
   Lancet Gastroenterol Hepatol, 8 (10), 879-907
   DOI 10.1016/S2468-1253(23)00197-8, PubMed 37517414

Publications 2022

1. Haukeland JW, Midgard H, Konopski Z, Sarna VK, Grøtta OJ, Kløw NE (2022)
   [Transjugular intrahepatic portosystemic shunt for portal hypertension]
   Tidsskr Nor Laegeforen, 142 (14)
   DOI 10.4045/tidsskr.21.0911, PubMed 36226423
2. Midgard H, Bjørnestad R, Egeland M, Dahl E, Finbråten AK, Kielland KB, Blindheim M, Dalgard O (2022)
   Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs
   Liver Int, 42 (6), 1268-1277
   DOI 10.1111/liv.15266, PubMed 35362660
3. Polaris Observatory HCV Collaborators (2022)
   Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
   Lancet Gastroenterol Hepatol, 7 (5), 396-415
   DOI 10.1016/S2468-1253(21)00472-6, PubMed 35180382
4. Vesterhus M, Jørgensen KK, Frigstad SO, Haukeland JW, Karlsen TH (2022)
   [We need a new strategy for liver disease]
   Tidsskr Nor Laegeforen, 142 (3)
   DOI 10.4045/tidsskr.21.0892, PubMed 35170917

Publications 2021

1. Busschots D, Bielen R, Koc ÖM, Heyens L, Verrando R, de Galocsy C, Van Steenkiste C, Nevens F, Midgard H, Dalgard O, Robaeys G (2021)
   Hepatitis C reinfection in former and active injecting drug users in Belgium
   Harm Reduct J, 18 (1), 102
   DOI 10.1186/s12954-021-00552-x, PubMed 34641896
2. Dalgard O, Midgard H, Kielland KB (2021)
   Hepatitis C in Iceland: a milestone for global elimination
   Lancet Gastroenterol Hepatol, 6 (8), 599-600
   DOI 10.1016/S2468-1253(21)00182-5, PubMed 34171268
3. Fadnes LT, Aas CF, Vold JH, Leiva RA, Ohldieck C, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA, INTRO-HCV Study Group (2021)
   Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV)
   PLoS Med, 18 (6), e1003653
   DOI 10.1371/journal.pmed.1003653, PubMed 34061883
4. Hoffmann-Vold AM, Fretheim HH, Sarna VK, Barua I, Carstens MN, Distler O, Khanna D, Volkmann ER, Midtvedt Ø, Didriksen H, Dhainaut A, Halse AK, Bakland G, Pesonen M, Olsen I, Molberg Ø (2021)
   Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial
   BMJ Open, 11 (6), e048541
   DOI 10.1136/bmjopen-2020-048541, PubMed 34168032
5. Midgard H, Ulstein K, Backe Ø, Foshaug T, Sørli H, Vennesland K, Nilssen D, Dahl EH, Finbråten AK, Wüsthoff L, Dalgard O (2021)
   Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway
   Int J Drug Policy, 96, 103165
   DOI 10.1016/j.drugpo.2021.103165, PubMed 33642182
6. Stamnaes J, Stray D, Stensland M, Sarna VK, Nyman TA, Lundin KEA, Sollid LM (2021)
   In Well-Treated Celiac Patients Low-Level Mucosal Inflammation Predicts Response to 14-day Gluten Challenge
   Adv Sci (Weinh), 8 (4), 2003526
   DOI 10.1002/advs.202003526, PubMed 33643806
7. Tjønnfjord SKV, Tjønnfjord EB, Konopski Z, Tjønnfjord GE (2021)
   Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia
   Case Rep Hematol, 2021, 1862446
   DOI 10.1155/2021/1862446, PubMed 34721911
8. Vesterhus M, Wiencke K, Haukeland JW, Frigstad SO, Karlsen LN, Jørgensen KK, Folseraas T (2021)
   [Diagnosis and treatment of autoimmune hepatitis]
   Tidsskr Nor Laegeforen, 141 (10)
   DOI 10.4045/tidsskr.20.1045, PubMed 34182737

Publications 2020

1. Haukeland JW, Småstuen MC, Pålsdatter PP, Ismail M, Konopski Z, Jørgensen KK, Lannerstedt H, Midgard H (2020)
   Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway
   PLoS One, 15 (3), e0230263
   DOI 10.1371/journal.pone.0230263, PubMed 32163489
2. Midgard H, Finbråten AK, Malme KB, Berg-Pedersen RM, Tanum L, Olsen IC, Bjørnestad R, Dalgard O (2020)
   Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs
   Trials, 21 (1), 524
   DOI 10.1186/s13063-020-04434-8, PubMed 32539853
3. Sarna VK, Lunding J, Loberg EM, Solberg IC (2020)
   A man in his 50s with chronic diarrhea and weight loss
   Tidsskr. Nor. Laegeforen., 140 (11), 1148-1151
4. Sarna VK, Lunding J, Løberg EM, Solberg IC (2020)
   [A man in his fifties with chronic diarrhoea and weight loss]
   Tidsskr Nor Laegeforen, 140 (11)
   DOI 10.4045/tidsskr.19.0812, PubMed 32815334

Publications 2019

1. Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA, INTRO-HCV Study Group (2019)
   Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV)
   BMC Infect Dis, 19 (1), 943
   DOI 10.1186/s12879-019-4598-7, PubMed 31703669
2. Gidoni M, Snir O, Peres A, Polak P, Lindeman I, Mikocziova I, Sarna VK, Lundin KEA, Clouser C, Vigneault F, Collins AM, Sollid LM, Yaari G (2019)
   Mosaic deletion patterns of the human antibody heavy chain gene locus shown by Bayesian haplotyping
   Nat Commun, 10 (1), 628
   DOI 10.1038/s41467-019-08489-3, PubMed 30733445
3. Goel G, Tye-Din JA, Qiao SW, Russell AK, Mayassi T, Ciszewski C, Sarna VK, Wang S, Goldstein KE, Dzuris JL, Williams LJ, Xavier RJ, Lundin KEA, Jabri B, Sollid LM, Anderson RP (2019)
   Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease
   Sci Adv, 5 (8), eaaw7756
   DOI 10.1126/sciadv.aaw7756, PubMed 31457091
4. Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, Midgard H, Dalgard O, Dillon J, Hickman M, Bruneau J, Dore GJ, Grebely J (2019)
   Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis
   J Hepatol, 72 (4), 643-657
   DOI 10.1016/j.jhep.2019.11.012, PubMed 31785345
5. Safreed-Harmon K, Blach S, Aleman S, Bollerup S, Cooke G, Dalgard O, Dillon JF, Dore GJ, Duberg AS, Grebely J, Boe Kielland K, Midgard H, Porter K, Razavi H, Tyndall M, Weis N, Lazarus JV (2019)
   The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination
   Clin Infect Dis, 69 (12), 2218-2227
   DOI 10.1093/cid/ciz714, PubMed 31352481
6. Shridhar Gulati R, Wimalanathan T, Norheim Andersen S, Isaksen K, Lagging M, Midgard H, Moghaddam A, Dalgard O (2019)
   The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients
   Scand J Gastroenterol, 54 (9), 1172-1175
   DOI 10.1080/00365521.2019.1643403, PubMed 31479286
7. Tye-Din JA, Skodje GI, Sarna VK, Dzuris JL, Russell AK, Goel G, Wang S, Goldstein KE, Williams LJ, Sollid LM, Lundin KE, Anderson RP (2019)
   Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity
   United European Gastroenterol J, 8 (1), 108-118
   DOI 10.1177/2050640619874173, PubMed 32213060
8. Øvrehus ALH, Midgard H (2019)
   How can we achieve WHO's elimination target for hepatitis C incidence?
   Lancet Gastroenterol Hepatol, 4 (6), 415-417
   DOI 10.1016/S2468-1253(19)30120-7, PubMed 30981687

Publications 2018

1. Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J, International Network on Hepatitis in Substance Users (INHSU) (2018)
   Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework
   Liver Int, 39 (1), 20-30
   DOI 10.1111/liv.13949, PubMed 30157316
2. Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Matičič M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M (2018)
   Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
   J Hepatol, 68 (3), 402-411
   DOI 10.1016/j.jhep.2017.10.010, PubMed 29080808
3. Midgard H (2018)
   Hepatitis C in drug addicts
   Tidsskr. Nor. Laegeforen., 138 (13), 1243
4. Midgard H, Kielland KB, Dalgard O (2018)
   [Elimination of hepatitis C is possible]
   Tidsskr Nor Laegeforen, 138 (7)
   DOI 10.4045/tidsskr.18.0099, PubMed 29663789
5. Midgard H, Kielland KB, Dalgard O (2018)
   Elimination of Hepatitis C is possible
   Tidsskr. Nor. Laegeforen., 138 (7), 630-633
6. Risnes LF, Christophersen A, Dahal-Koirala S, Neumann RS, Sandve GK, Sarna VK, Lundin KE, Qiao SW, Sollid LM (2018)
   Disease-driving CD4+ T cell clonotypes persist for decades in celiac disease
   J Clin Invest, 128 (6), 2642-2650
   DOI 10.1172/JCI98819, PubMed 29757191

Publications 2017

1. Bjøro B, Dalgard O, Midgard H, Verbaan H, Småstuen MC, Rustøen T (2017)
   Increased hope following successful treatment for hepatitis C infection
   J Adv Nurs, 74 (3), 724-733
   DOI 10.1111/jan.13487, PubMed 29082540
2. Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J, ACTIVATE Study Group (2017)
   Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
   BMC Infect Dis, 17 (1), 420
   DOI 10.1186/s12879-017-2517-3, PubMed 28610605
3. Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L, Midgard H, Larney S, Degenhardt L, Alho H, Byrne J, Dillon JF, Feld JJ, Foster G, Goldberg D, Lloyd AR, Reimer J, Robaeys G, Torrens M, Wright N, Maremmani I et al. (2017)
   Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
   Int J Drug Policy, 47, 51-60
   DOI 10.1016/j.drugpo.2017.05.019, PubMed 28683982
4. Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ, ACTIVATE Study Group (2017)
   Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
   Int J Drug Policy, 47, 177-186
   DOI 10.1016/j.drugpo.2017.05.020, PubMed 28624134
5. Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J, ACTIVATE Study Group (2017)
   Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study
   Int J Drug Policy, 47, 230-238
   DOI 10.1016/j.drugpo.2017.05.040, PubMed 28633998
6. Sarna VK, Lundin KEA, Mørkrid L, Qiao SW, Sollid LM, Christophersen A (2017)
   HLA-DQ-Gluten Tetramer Blood Test Accurately Identifies Patients With and Without Celiac Disease in Absence of Gluten Consumption
   Gastroenterology, 154 (4), 886-896.e6
   DOI 10.1053/j.gastro.2017.11.006, PubMed 29146521
7. Sarna VK, Skodje GI, Reims HM, Risnes LF, Dahal-Koirala S, Sollid LM, Lundin KEA (2017)
   HLA-DQ:gluten tetramer test in blood gives better detection of coeliac patients than biopsy after 14-day gluten challenge
   Gut, 67 (9), 1606-1613
   DOI 10.1136/gutjnl-2017-314461, PubMed 28779027
8. Skodje GI, Sarna VK, Minelle IH, Rolfsen KL, Muir JG, Gibson PR, Veierød MB, Henriksen C, Lundin KEA (2017)
   Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity
   Gastroenterology, 154 (3), 529-539.e2
   DOI 10.1053/j.gastro.2017.10.040, PubMed 29102613

Publications 2016

1. Midgard H, Bjøro B, Mæland A, Konopski Z, Kileng H, Damås JK, Paulsen J, Heggelund L, Sandvei PK, Ringstad JO, Karlsen LN, Stene-Johansen K, Pettersson JH, Dorenberg DH, Dalgard O (2016)
   Hepatitis C reinfection after sustained virological response
   J Hepatol, 64 (5), 1020-1026
   DOI 10.1016/j.jhep.2016.01.001, PubMed 26780289
2. Midgard H, Bramness JG, Skurtveit S, Haukeland JW, Dalgard O (2016)
   Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study
   PLoS One, 11 (11), e0166451
   DOI 10.1371/journal.pone.0166451, PubMed 27846264
3. Midgard H, Weir A, Palmateer N, Lo Re V, Pineda JA, Macías J, Dalgard O (2016)
   HCV epidemiology in high-risk groups and the risk of reinfection
   J Hepatol, 65 (1 Suppl), S33-S45
   DOI 10.1016/j.jhep.2016.07.012, PubMed 27641987

Publications 2015

1. Hauge T, Hauge PW, Warloe T, Drolsum A, Johansen C, Viktil E, Aabakken L, Buanes T, Konopski Z (2015)
   Randomised controlled trial of temoporfin photodynamic therapy plus chemotherapy in nonresectable biliary carcinoma--PCS Nordic study
   Photodiagnosis Photodyn Ther, 13, 330-333
   DOI 10.1016/j.pdpdt.2015.09.004, PubMed 26415549
2. Otterdal K, Haukeland JW, Yndestad A, Dahl TB, Holm S, Segers FM, Gladhaug IP, Konopski Z, Damås JK, Halvorsen B, Aukrust P (2015)
   Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation
   Clin Transl Gastroenterol, 6 (7), e95
   DOI 10.1038/ctg.2015.23, PubMed 26133108

Publications 2013

1. von Volkmann HL, Havre RF, Løberg EM, Haaland T, Immervoll H, Haukeland JW, Hausken T, Gilja OH (2013)
   Quantitative measurement of ultrasound attenuation and Hepato-Renal Index in Non-Alcoholic Fatty Liver Disease
   Med Ultrason, 15 (1), 16-22
   DOI 10.11152/mu.2013.2066.151.hlv1qmu2, PubMed 23486619

Publications 2012

1. Lannerstedt H, Konopski Z, Sandvik L, Haaland T, Løberg EM, Haukeland JW (2012)
   Combining transient elastography with FIB4 enhances sensitivity in detecting advanced fibrosis of the liver
   Scand J Gastroenterol, 48 (1), 93-100
   DOI 10.3109/00365521.2012.746389, PubMed 23205894
2. Sarna VK, Stray N (2012)
   A young woman with upper gastrointestinal bleeding
   Tidsskr Nor Laegeforen, 132 (18), 2070-2
   DOI 10.4045/tidsskr.11.1197, PubMed 23038199

Publications 2011

1. Andersen ES, Weiland O, Leutscher P, Krarup H, Westin J, Moessner B, Konopski Z, Frigstad SO, Kjær M, Christensen PB, Weis N (2011)
   Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs
   Scand J Gastroenterol, 46 (6), 760-6
   DOI 10.3109/00365521.2011.565068, PubMed 21438780
2. Florholmen J, Kristiansen MG, Steigen SE, Sørbye SW, Paulssen EJ, Kvamme JM, Konopski Z, Gutteberg T, Goll R (2011)
   A rapid chemokine response of macrophage inflammatory protein (MIP)-1α, MIP-1β and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C
   Clin Microbiol Infect, 17 (2), 204-9
   DOI 10.1111/j.1469-0691.2010.03206.x, PubMed 20219081
3. Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Løberg EM, Haaland T, Konopski Z, Wium C, Aasheim ET, Johansen OE, Aukrust P, Halvorsen B, Birkeland KI (2011)
   Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies
   Eur J Endocrinol, 166 (3), 503-10
   DOI 10.1530/EJE-11-0864, PubMed 22170794
4. Yndestad A, Haukeland JW, Dahl TB, Halvorsen B, Aukrust P (2011)
   Activin A in nonalcoholic fatty liver disease
   Vitam Horm, 85, 323-42
   DOI 10.1016/B978-0-12-385961-7.00015-9, PubMed 21353887

Publications 2010

1. Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, Damås JK, Haaland T, Løberg EM, Arntsen B, Birkeland K, Bjøro K, Ulven SM, Konopski Z, Nebb HI, Aukrust P, Halvorsen B (2010)
   Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease
   J Clin Endocrinol Metab, 95 (6), 3039-47
   DOI 10.1210/jc.2009-2148, PubMed 20392873
2. Midgard H, Bang C, Raknerud N, Dalgard O (2010)
   Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin
   Scand J Gastroenterol, 45 (12), 1503-8
   DOI 10.3109/00365521.2010.510571, PubMed 20698740

Publications 2009

1. Haukeland JW, Konopski Z, Eggesbø HB, von Volkmann HL, Raschpichler G, Bjøro K, Haaland T, Løberg EM, Birkeland K (2009)
   Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial
   Scand J Gastroenterol, 44 (7), 853-60
   DOI 10.1080/00365520902845268, PubMed 19811343
2. Yndestad A, Haukeland JW, Dahl TB, Bjøro K, Gladhaug IP, Berge C, Damås JK, Haaland T, Løberg EM, Linnestad P, Birkeland K, Konopski Z, Halvorsen B, Berge RK, Aukrust P (2009)
   A complex role of activin A in non-alcoholic fatty liver disease
   Am J Gastroenterol, 104 (9), 2196-205
   DOI 10.1038/ajg.2009.318, PubMed 19532130
3. Aasheim ET, Frigstad SO, Søvik TT, Birkeland KI, Haukeland JW (2009)
   Hyperinsulinemic hypoglycemia and liver cirrhosis presenting after duodenal switch: a case report
   Surg Obes Relat Dis, 6 (4), 441-3
   DOI 10.1016/j.soard.2009.11.007, PubMed 20096646

Publications 2008

1. Haukeland JW, Schreiner LT, Lorgen I, Frigstad SO, Bang C, Raknerud N, Konopski Z (2008)
   ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis
   Scand J Gastroenterol, 43 (10), 1241-8
   DOI 10.1080/00365520802158614, PubMed 18609128

Publications 2007

1. Haukeland JW, Bjøro K (2007)
   [When the brain fails in liver failure]
   Tidsskr Nor Laegeforen, 127 (11), 1490
   PubMed 17551548
2. Haukeland JW, Lorgen I, Schreiner LT, Frigstad SO, Brandsaeter B, Bjøro K, Bang C, Raknerud N, Konopski Z (2007)
   Incidence rates and causes of cirrhosis in a Norwegian population
   Scand J Gastroenterol, 42 (12), 1501-8
   DOI 10.1080/00365520701478014, PubMed 17852839
3. Moum B, Konopski Z, Tufteland KF, Jahnsen J (2007)
   Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab
   Inflamm Bowel Dis, 13 (12), 1584-6
   DOI 10.1002/ibd.20230, PubMed 17663423

Publications 2006

1. Haukeland JW, Aukrust P (2006)
   Inflammatory interactions between nonalcoholic fatty liver disease and the metabolic syndrome
   J. Hepatol., 45 (6), 881-882
   DOI 10.1016/j.jhep.2006.09.006
2. Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K, Aukrust P (2006)
   Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2
   J Hepatol, 44 (6), 1167-74
   DOI 10.1016/j.jhep.2006.02.011, PubMed 16618517

Publications 2005

1. Haukeland JW, Konopski Z, Linnestad P, Azimy S, Marit Løberg E, Haaland T, Birkeland K, Bjøro K (2005)
   Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease
   Scand J Gastroenterol, 40 (12), 1469-77
   DOI 10.1080/00365520500264953, PubMed 16293559

Publications 2001

1. Haukeland JW, Konopski Z, Bell H, Raknerud N (2001)
   [Non-alcoholic steatohepatitis]
   Tidsskr Nor Laegeforen, 121 (20), 2377-80
   PubMed 11603045

Publications 2000

1. Haukeland JW, Jahnsen J, Raknerud N (2000)
   [Carbamazepine-induced hepatitis]
   Tidsskr Nor Laegeforen, 120 (24), 2875-7
   PubMed 11143408

Publications 1999

1. Haukeland JW, Bøhmer T (1999)
   [Severe hypophosphatemia--an overlooked condition?]
   Tidsskr Nor Laegeforen, 119 (4), 538-40
   PubMed 10081379

Publications 1996

1. Haukeland JW (1996)
   [Seroxat combined with Meravean--increased risk of hemorrhage?]
   Tidsskr Nor Laegeforen, 116 (29), 3528-9
   PubMed 9019863

Publications 1995

1. Konopski Z, Fandrem J, Seljelid R, Eskeland T (1995)
   Interferon-gamma inhibits endocytosis of soluble animated beta-1,3-D-glucan and neutral red in mouse peritoneal macrophages
   J Interferon Cytokine Res, 15 (7), 597-603
   DOI 10.1089/jir.1995.15.597, PubMed 7553229

Publications 1994

1. Busund R, Rønning G, Lindsetmo RO, Busund LT, Mollnes TE, Konopski Z, Revhaug A (1994)
   The effects of plasma and albumin infusion on organ function and sepsis markers in experimental gram-negative sepsis
   Shock, 2 (6), 402-7
   DOI 10.1097/00024382-199412000-00003, PubMed 7743369
2. Konopski Z, Seljelid R, Eskeland T (1994)
   IFN-gamma inhibits internalization of soluble aminated beta-1,3-D-glucan by macrophages and thereby down-regulates the glucan induced release of TNF-alpha and IL-1 beta
   Scand J Immunol, 40 (1), 57-63
   DOI 10.1111/j.1365-3083.1994.tb03433.x, PubMed 8029644
3. Konopski Z, Smedsrød B, Seljelid R, Eskeland T (1994)
   A novel immunomodulator soluble aminated beta-1,3-D-glucan: binding characteristics to mouse peritoneal macrophages
   Biochim Biophys Acta, 1221 (1), 61-5
   DOI 10.1016/0167-4889(94)90216-x, PubMed 8130277
4. Rekdal O, Konopski Z, Svendsen JS, Winberg JO, Espevik T, Osterud B (1994)
   The TNF Receptors p55 and p75 Mediate Chemotaxis of PMN Induced by TNFalpha and a TNFalpha 36-62 Peptide
   Mediators Inflamm, 3 (5), 347-52
   DOI 10.1155/S0962935194000487, PubMed 18475579

Publications 1993

1. Konopski Z, Seljelid R, Eskeland T (1993)
   Cytokines and PGE2 modulate the phagocytic function of the beta-glucan receptor in macrophages
   Scand J Immunol, 37 (5), 587-92
   DOI 10.1111/j.1365-3083.1993.tb02576.x, PubMed 8387227

Publications 1992

1. Rasmussen Busund LT, Konopski Z, Oian P, Seljelid R (1992)
   Killing of Escherichia coli by mononuclear phagocytes and neutrophils stimulated in vitro with beta-1,3-D-polyglucose derivatives
   Microbiol Immunol, 36 (11), 1173-88
   DOI 10.1111/j.1348-0421.1992.tb02120.x, PubMed 1491620

Publications 1991

1. Konopski Z, Rasmussen LT, Seljelid R, Eskeland T (1991)
   Phagocytosis of beta-1,3-D-glucan-derivatized microbeads by mouse peritoneal macrophages involves three different receptors
   Scand J Immunol, 33 (3), 297-306
   DOI 10.1111/j.1365-3083.1991.tb01775.x, PubMed 1849314